Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 5/20 | 0.51 |
| ▸ | HTR2B | P41595 | 5/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654490 | 1.00 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3KCNH2REN | |
| SCHEMBL654966 | 1.00 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3KCNH2REN | |
| Hydrochloric Acid SCHEMBL5811325 | 0.98 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2REN | |
| Formic Acid SCHEMBL31071560 | 0.91 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3KCNH2REN | |
| SCHEMBL13886623 | 0.90 | CHRNB2 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2REN | |
| SCHEMBL4471193 | 0.90 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2REN | |
| Hydrochloric Acid SCHEMBL19921391 | 0.88 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3KCNH2REN | |
| SCHEMBL2069846 | 0.86 | CHRNB2 (0.54) | SLC6A4SLC6A2SLC6A3KCNH2REN | |
| SCHEMBL17460169 | 0.86 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3RENHTR2C | |
| SCHEMBL21638189 | 0.83 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3KCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023147571-A2 | SELECTIVE AGENTS TARGETING MYCOBACTERIUM TUBERCULOSIS | UNIVERSITY OF MISSISSIPPI (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-1688418-B1 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARM INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-1950198-B1 | PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE | TORAY FINECHEMICALS CO LTD (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| CN-101300228-B | Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative | TORAY FINECHEMICALS CO LTD | 2013-05-08 | — | — | CN | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| CN-1426393-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-06-25 | — | — | CN | disclosed |
| CN-1426394-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-06-25 | — | — | CN | disclosed |
| CN-1426412-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-06-25 | — | — | CN | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1263760-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263725-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263724-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062757-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062729-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062728-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | SLC6A4 1469/4885SLC6A2 976/4885SLC6A3 1141/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | SLC6A4 1469/4885SLC6A2 976/4885SLC6A3 1141/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | SLC6A4 1469/4885SLC6A2 976/4885SLC6A3 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.